Histone deacetylase inhibitors: A potential epigenetic treatment for Duchenne muscular dystrophy

Epigenomics

Volumn 6, Issue 5, 2014, Pages 547-560

  Consalvi, Silvia ^a   Saccone, Valentina ^a   Mozzetta, Chiara ^b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b CNR   (Italy)

Author keywords

chromatin; epigenetics; HDAC inhibitors; muscle stem cells; muscular dystrophy; regeneration

Indexed keywords

DYSTROPHIN; GIVINOSTAT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; MYOD PROTEIN; MYOGENIC FACTOR 5; MYOGENIN; NITRIC OXIDE SYNTHASE; POLYCOMB REPRESSIVE COMPLEX 2; CARBAMIC ACID DERIVATIVE; HISTONE;

ADIPOCYTE; AGING; BASEMENT MEMBRANE; BLOOD VESSEL; CELL DIFFERENTIATION; DUCHENNE MUSCULAR DYSTROPHY; EOSINOPHIL; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROBLAST; GENETIC REGULATION; HISTONE ACETYLATION; HUMAN; MACROPHAGE; MULTINUCLEAR CELL; MUSCLE DEVELOPMENT; MUSCLE REGENERATION; MUSCLE STEM CELL; MYOBLAST; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SATELLITE CELL; SKELETAL MUSCLE; ACETYLATION; ANIMAL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; REGENERATION; SKELETAL MUSCLE SATELLITE CELL;

ACETYLATION; ANIMALS; CARBAMATES; CELL DIFFERENTIATION; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; REGENERATION; SATELLITE CELLS, SKELETAL MUSCLE;

EID: 84913616554     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.36     Document Type: Review

References (100)

1. Mercuri E, Muntoni F. Muscular dystrophies. Lancet 381, 845-860 (2013).
2. Bonilla E, Samitt CE, Miranda AF et al. Duchenne muscul dystrophy: defciency of dystrophin at the muscle cell surfac Cell 54(4), 447-452 (1988).
3. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51(6), 919-928 (1987).
4. Ervasti JM. Dystrophin, its interactions with other proteins and implications for muscular dystrophy. Biochim. Biophys. Acta 1772(2), 108-117 (2007).
5. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell K P. Defciency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345(6273),, 315-319 (1990).
6. Benedetti S, Hoshiya H, Tedesco FS. Repair or replace? Exploiting novel gene and cell therapy strategies for muscula dystrophies. FEBS J. 280(17), 4263-4280 (2013).
7. Mozzetta C, Minetti G, Puri PL. Regenerative pharmacolog in the treatment of genetic diseases: the paradigm of muscular dystrophy. Int. J. Biochem. Cell Biol. 41(4), 701-710 (2009).
8. Fairclough RJ, Perkins KJ, Davies KE. Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy. Curr. Gene Ther. 12(3), 206-244 (2012).
9. Chargé SBP, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol. Rev. 84(1), 209-238 (2004).
10. Wang YX, Rudnicki MA. Satellite cells, the engines of muscl repair. Nat. Rev. Mol. Cell Biol. 13(2), 127-133 (2012).
11. Brack AS, Rando TA. Tissue-specifc stem cells: lessons from the skeletal muscle satellite cell. Cell Stem Cell 10 (5), 504-514 (2012).
12. Collins CA, Olsen I, Zammit PS et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell 122(2), 289-301 (2005).
13. Sousa-Victor P, Gutarra S, García-Prat L et al. Geriatric muscle stem cells switch reversible quiescence into senescence. Nature 506(7488), 316-321 (2014).
14. Carlson ME, Conboy IM. Loss of stem cell regenerative capacity within aged niches. Aging Cell 6( 3), 371-382 ( 2007).
15. Sacco A, Mourkioti F, Tran R et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 143(7), 1059-1071 (2010).
16. Bentzinger CF, Wang YX, Dumont NA, Rudnicki MA. Cellular dynamics in the muscle satellite cell niche. EMBO Rep. 14(12), 1062-1072 (2013).
17. Judson RN, Zhang RH, Rossi FM. Tissue-resident mesenchymal stem/progenitor cells in skeletal muscle: collaborators or saboteurs? FEBS J. 280(17), 4100-4108 (2013).
18. Sampaolesi M, Blot S, DAntona G et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444(7119), 574-579 (2006).
19. Sampaolesi M, Torrente Y, Innocenzi A et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301(5632), 487-492 (2003).
20. Dellavalle A, Sampaolesi M, Tonlorenzi R et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol. 9(3), 255-267 (2007).
21. Dellavalle A, Maroli G, Covarello D et al. Pericytes resident in postnatal skeletal muscle differentiate into muscle fbres and generate satellite cells. Nat. Commun. 11(2), 499 (2011).
22. Asakura A, Seale P, Girgis-Gabardo A, Rudnicki MA. Myogenic specifcation of side population cells in skeletal muscle. J. Cell Biol. 159(1), 123-134 (2002).
23. Uezumi A, Ojima K, Fukada S et al. Functional heterogeneity of side population cells in skeletal muscle. Biochem. Biophys. Res. Commun. 341(3), 864-873 (2006).
24. Gussoni E, Soneoka Y, Strickland CD et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401(6751), 390-394 (1999).
25. Mitchell KJ, Pannérec A, Cadot B et al. Identifcation and characterization of a non-satellite cell muscle resident progenitor during postnatal development. Nat. Cell Biol. 12(3), 257-266 (2010).
26. Saccone V, Consalvi S, Giordani L et al. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fbro-adipogenic progenitors in dystrophic muscles. Genes Dev. 28(8), 841-857 (2014).
27. Joe AWB, Yi L, Natarajan A et al. Muscle injury activates resident fbro/adipogenic progenitors that facilitate myogenesis. Nat. Cell Biol. 12(2), 153-163 (2010).
28. Uezumi A, Fukada S, Yamamoto N, Takeda S, Tsuchida K. Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat. Cell Biol. 12(2), 143-152 (2010).
29. Mozzetta C, Consalvi S, Saccone V et al. Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice. EMBO Mol. Med. 5(4), 626-639 (2013).
30. Uezumi A, Ito T, Morikawa D et al. Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. J. Cell Sci. 124(Pt 21), 3654-3664 (2011).
31. Dulauroy S, Di Carlo SE, Langa F, Eberl G, Peduto L. Lineage tracing and genetic ablation of ADAM12#sup#+#/sup# perivascular cells identify a major source of profbrotic cells during acute tissue injury Nat. Med. 18(8), 1262-1270 (2012).
32. Heredia JE, Mukundan L, Chen FM et al. Type 2 innate signals stimulate fbro/adipogenic progenitors to facilitate muscle regeneration. Cell 153(2), 376-388 (2013).
33. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298(5), R1173-R1187 (2010).
34. Brunelli S, Rovere-Querini P. The immune system and the repair of skeletal muscle. Pharmacol. Res. 58(2), 117-121 (2008).
35. Brack AS, Conboy MJ, Roy S et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fbrosis. Science 317(5839), 807-810 (2007).
36. Chakkalakal J V, Jones KM, Basson MA, Brack AS. The aged niche disrupts muscle stem cell quiescence. Nature 490(7420), 355-360 (2012).
37. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433(7027), 760-764 (2005).
38. Carlson ME, Suetta C, Conboy MJ et al. Molecular aging and rejuvenation of human muscle stem cells. EMBO Mol. Med. 1(8-9), 381-391 (2009).
39. Penton CM, Thomas-Ahner JM, Johnson EK, McAllister C, Montanaro F. Muscle side population cells from dystrophic or injured muscle adopt a fbro-adipogenic fate. PLoS One 8(1), e54553 (2013).
40. Yin H, Pasut A, Soleimani VD et al. Article microRNA-133 controls brown adipose determination in skeletal muscle satellite cells by targeting Prdm16. Cell Metab. 17(2), 210-224 (2013).
41. Cencetti F, Bernacchioni C, Nincheri P, Donati C, Bruni P. Transforming growth factor-beta1 induces transdifferentiation of myoblasts into myofbroblasts via up-regulation of sphingosine kinase-1/S1P3 axis. Mol. Biol. Cell 21(6), 1111-1124 (2010).
42. Asakura A, Komaki M, Rudnicki M. Muscle satellite cells are multipotential stem cells that exhibit myogenic, osteogenic, and adipogenic differentiation. Differentiation 68(4-5), 245-253 (2001).
43. Sartorelli V, Juan AH. Sculpting chromatin beyond the double helix: epigenetic control of skeletal myogenesis. Curr. Top. Dev. Biol. 96, 57-83 (2011).
44. Guasconi V, Puri PL. Chromatin: the interface between extrinsic cues and the epigenetic regulation of muscle regeneration. Trends Cell Biol. 19(6), 286-294 (2009).
45. Giordani L, Puri PL. Epigenetic control of skeletal muscle regeneration: integrating genetic determinants and environmental changes. FEBS J. 280(17), 4014-4025 (2013).
46. Kouzarides T Chromatin modifcations and their function. Cell 128(4), 693-705 (2007).
47. Puri PL, Sartorelli V. Regulation of muscle regulatory factors by DNA-binding, interacting proteins, and post-transcriptional modifcations. J. Cell. Physiol. 185(2), 155-173 (2000).
48. McKinsey TA, Zhang CL, Olson EN. Control of muscle development by dueling HATs and HDACs. Curr. Opin. Genet. Dev. 11(5), 497-504 (2001).
49. Puri PL, Iezzi S, Stiegler P et al. Class I histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis. Mol. Cell 8(4), 885-897 (2001).
50. Lu J, McKinsey TA, Zhang CL, Olson EN. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol. Cell 6(2), 233-244 (2000).
51. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 408(6808), 106-111 (2000).
52. Iezzi S, Di Padova M, Serra C et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev. Cell 6(5), 673-684 (2004).
53. Iezzi S, Cossu G, Nervi C, Sartorelli V, Puri PL. Stage-specifc modulation of skeletal myogenesis by inhibitors of nuclear deacetylases. Proc. Natl Acad. Sci. USA 99(11), 7757-7762 (2002).
54. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 13(5), 343-357 (2012).
55. Asp P, Blum R, Vethantham V et al. Genome-wide remodeling of the epigenetic landscape during myogenic differentiation. Proc. Natl Acad. Sci. USA 108(22), E149-E158 (2011).
56. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev. 18(21), 2627-2638 (2004).
57. Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V. Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol. Cell 36(1), 61-74 (2009).
58. Juan AH, Derfoul A, Feng X et al. Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells. Genes Dev. 25(8), 789-794 (2011).
59. Mozzetta C, Consalvi S, Saccone V, Forcales S V, Puri PL, Palacios D. Selective control of Pax7 expression by TNF-activated p38a/polycomb repressive complex 2 (PRC2) signaling during muscle satellite cell differentiation. Cell Cycle 10(2), 191-198 (2011).
60. Palacios D, Mozzetta C, Consalvi S et al. TNF/p38a/ polycomb signaling to Pax7 locus in satellite cells links infammation to the epigenetic control of muscle regeneration. Cell Stem Cell 7(4), 455-469 (2010).
61. Seenundun S, Rampalli S, Liu Q-C et a l. UTX mediates demethylation of H3K27me3 at muscle-specifc genes during myogenesis. EMBO J. 29(8), 1401-1411 (2010).
62. Stojic L, Jasencakova Z, Prezioso C et al. Chromatin regulated interchange between polycomb repressive complex 2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal muscle cells. Epigenetics Chromatin 5(4), 16 (2011).
63. Robson LG, Di Foggia V, Radunovic A, Bird K, Zhang X, Marino S. Bmi1 is expressed in postnatal myogenic satellite cells, controls their maintenance and plays an essential role in repeated muscle regeneration. PLoS One 6(11), e27116 (2011).
64. Ait-Si-Ali S, Guasconi V, Fritsch L et al. A Suv39h-dependent mechanism for silencing S-phase genes in differentiating but not in cycling cells. EMBO J. 23 (3), 605-615 (2004).
65. Guasconi V, Pritchard L-L, Fritsch L et al. Preferential association of irreversibly silenced E2F-target genes with pericentromeric heterochromatin in differentiated muscle cells. Epigenetics 5(8), 704-709 (2010).
66. Zhang C, McKinsey T, Olson E. Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol. Cell. Biol. 22(20), 7302-7312 (2002).
67. Mal AK. Histone methyltransferase Suv39h1 represses MyoD-stimulated myogenic differentiation. EMBO J. 25(14), 3323-3334 (2006).
68. Gillespie MA, Le Grand F, Scimè A et al. P38-{gamma}-dependent gene silencing restricts entry into the myogenic differentiation program. J. Cell Biol. 187(7), 991-1005 (2009).
69. Ling BMT, Bharathy N, Chung T-K et al. Lysine methyltransferase G9a methylates the transcription factor MyoD and regulates skeletal muscle differentiation. Proc. Natl Acad. Sci. USA 109(3), 841-846 (2012).
70. Ohno H, Shinoda K, Ohyama K, Sharp LZ, Kajimura S. EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex. Nature 16504 (7478), 163-167 (2013).
71. Seale P, Bjork B, Yang W et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature 454( 7207), 961-967 ( 2008).
72. Verrier L, Escafft F, Chailleux C, Trouche D, Vandromme M. A new isoform of the histone demethylase JMJD2A/ KDM4A is required for skeletal muscle differentiation. PLoS Genet. 7(6), e1001390 (2011).
73. Wang AH, Zare H, Mousavi K et al. The histone chaperone Spt6 coordinates histone H3K27 demethylation and myogenesis. EMBO J. 32, 1075-1086 (2013).
74. Rampalli S, Li L, Mak E et al. p38 MAPK signaling regulates recruitment of Ash2L-containing methyltransferase complexes to specifc genes during differentiation. Nat. Struct. Mol. Biol. 14(12), 1150-1156 (2007).
75. Liu L, Cheung TH, Charville GW et al. Resource chromatin modifcations as determinants of muscle stem cell quiescence and chronological aging. Cell Rep. 4(1), 189-204 (2013).
76. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11(5), 384-400 (2012).
77. Minetti GC, Colussi C, Adami R et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med. 12(10), 1147-1150 (2006).
78. Colussi C, Mozzetta C, Gurtner A et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl Acad. Sci. USA 105(49), 19183-19187 (2008).
79. Consalvi S, Mozzetta C, Bettica P et al. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol. Med. 20(19), 79-87 (2013).
80. Consalvi S, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL. Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases. Mol. Med. 17(5-6), 457-465.
81. Colussi C, Gurtner A, Rosati J et al. Nitric oxide defciency determines global chromatin changes in Duchenne muscular dystrophy. FASEB J. 23(7), 2131-2141 (2009).
82. Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82(5), 743-752 (1995).
83. Chao DS, Gorospe JR, Brenman JE et al. Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J. Exp. Med. 184(2), 609-618 (1996).
84. Nott A, Watson PM, Robinson JD, Crepaldi L, Riccio A. S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature 455(7211), 411-415 (2008).
85. Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J. Cell Biol. 155(1), 123-131 (2001).
86. Brunelli S, Sciorati C, D'Antona G et al. Nitric oxide release combined with nonsteroidal antiinfammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc. Natl Acad. Sci. USA 104(1), 264-269 (2007).
87. Pisconti A, Brunelli S, Di Padova M et al. Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion. J. Cell Biol. 172(2), 233-244 (2006).
88. Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 39(3), 283-296 (2009).
89. Cacchiarelli D, Martone J, Girardi E et al. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab. 12(4), 341-351 (2010).
90. Elaut G, Rogiers V, Vanhaecke T. The pharmaceutical potential of histone deacetylase inhibitors. Curr. Pharm. Des. 13(25), 2584-2620 (2007).
91. Ware CB, Wang L, Mecham BH et al. Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. Cell Stem Cell 4(4), 359-369 (2009).
92. Liang J, Wan M, Zhang Y et al. Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat. Cell Biol. 10(6), 731-739 (2008).
93. Karantzali E, Schulz H, Hummel O, Hubner N, Hatzopoulos A, Kretsovali A. Histone deacetylase inhibition accelerates the early events of stem cell differentiation: transcriptomic and epigenetic analysis. Genome Biol. 9(4), R65 (2008).
94. Bernstein BE, Mikkelsen TS, Xie X et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125(2), 315-326 (2006).
95. Mikkelsen TS, Ku M, Jaffe DB et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448(7153), 553-560 (2007).
96. Consalvi S, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL. Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases. Mol. Med. 17(5-6), 457-465 (2011).
97. Forcales S V, Albini S, Giordani L et al. Signal-dependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF chromatin-remodelling complex. EMBO J. 31(2), 301-316 (2011).
98. Colussi C, Banf C, Brioschi M et al. Proteomic profle of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment. Proteomics Clin. Appl. 4(1), 71-83 (2010).
99. Vojinovic J, Damjanov N, D'Urzo C et al. Safety and effcacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63(5), 1452-1458 (2011).
100. Furlan A, Monzani V, Reznikov LL et al. Pharmacokinetics, safety and inducible cytokine responses during a Phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17(5-6), 353-362 (2011).